Rhenman & Partners Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-302,157	Closed	-$1.24M	–	96
2018 Q1	$1.24M	Hold	302,157	–	–	0.15%	72
2017 Q4	$1.41M	Sell	302,157 -97,843	-24%	-$539K	0.19%	77
2017 Q3	$2.84M	Sell	400,000 -25,111	-6%	-$181K	0.36%	71
2017 Q2	$3.07M	Hold	425,111	–	–	0.44%	73
2017 Q1	$2.62M	Hold	425,111	–	–	0.41%	75
2016 Q4	$2.49M	Sell	425,111 -75,000	-15%	-$410K	0.48%	67
2016 Q3	$2.66M	Buy	500,111 +50,000	+11%	+$270K	0.42%	72
2016 Q2	$2.98M	Sell	450,111 -499,889	-53%	-$2.79M	0.53%	64
2016 Q1	$4.44M	Sell	950,000 -283,000	-23%	-$1.13M	0.88%	43
2015 Q4	$6.23M	Sell	1,233,000 -330,000	-21%	-$1.57M	0.94%	43
2015 Q3	$5.5M	Buy	1,563,000 +1,029,000	+193%	+$6.89M	0.88%	46
2015 Q2	$5.33M	Buy	534,000 +237,000	+80%	+$2.54M	0.64%	56
2015 Q1	$3.78M	Buy	297,000 +206,576	+228%	+$2.66M	0.64%	54
2014 Q4	$1.28M	Sell	90,424 -45,576	-34%	-$706K	0.37%	79
2014 Q3	$1.87M	Sell	136,000 -104,000	-43%	-$1.59M	0.55%	77
2014 Q2	$3.69M	Sell	240,000 -25,325	-10%	-$359K	1.1%	30
2014 Q1	$4.52M	Sell	265,325 -134,675	-34%	-$2.03M	1.36%	19
2013 Q4	$5.18M	Buy	+400,000	New	+$4.78M	2.03%	12

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PIMJS

PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rhenman & Partners Asset Management's KERX Position: Q2 2018 in Review

Rhenman & Partners Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 302,157 shares — an estimated $1.24M sold.

Rhenman & Partners Asset Management first reported a position in KERX in Q4 2013 and held it in 18 quarters. The position peaked at $6.23M in Q4 2015. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

Rhenman & Partners Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
Rhenman & Partners Asset Management sold 302,157 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $1.24M.
Rhenman & Partners Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 18 quarters.
Rhenman & Partners Asset Management's Keryx Biopharmaceuticals Inc position peaked at $6.23M in Q4 2015.
132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2018, filed 20 Jul 2018.